Mark R Spear (Mark Spear)

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Venues

Current cancer drug targets

Gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)
Brian Hetrick, Summer Siddiqui, Mark R Spear, Jia Guo, Huizhi Liang, Yajing Fu, Zhijun Yang, Lara A Doyle-Meyers, Bapi Pahar, Ronald S Veazey, Jason Dufour, Ali Andalibi, Binhua Ling, Yuntao Wu
Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques. Gene therapy (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)

Mark R Spear.css-eqlu8i{font-size:small;padding-left:4px;} (Mark Spear)

Publication Activity (10 Years)

Top Topics

Top Venues

Mark R Spear (Mark Spear)